innovaTV 301: Tisotumab Vedotin vs. Chemotherapy in Recurrent Cervical Cancer
Second- or third-line treatment with tisotumab vedotin significantly improves overall survival and progression-free survival compared to chemotherapy in patients with recurrent cervical cancer.